Imunus launches 2 new Aids molecules
24 Oct 2001
Mumbai:
Imunus,
the exclusive anti-retroviral division of the Hyderabad-based
Aurobindo Pharma Ltd, has introduced two more molecules
- Efavirenz (bulk drug name Viranz) and Nelfinavir (bulk
drug name Nelvex) - for
the treatment of Aids.
With this introduction, Aurobindo Pharma now offers more product
options for the treatment of Aids than any other pharmaceutical
company in India, a company statement claimed.
Imunus, our anti-retroviral division, was launched about five
months ago, and has been able, in a short time, to offer wider
product options than any other pharma company. Further, all these
products are competitively priced, reducing the overall cost of
HIV treatment, says Aurobindo Pharma vice-president A Hariharan.
Aurobindo Pharma is able to offer these drugs at such competitive
prices on account of its large-scale bulk manufacturing facilities
as well as strong in-house R&D capabilities. Aurobindos
R&D centre is also working on developing fixed dose
combination forms to reduce pill burden.
This will enable patients to adhere to the dosage of
the medicines, improve compliance and will further bring down the
overall cost of treatment.
Hariharan says that Imunus would soon start marketing anti-virals,
antibiotics and anti-fungal preparations for other infections
associated with HIV/Aids.
.webp)
.webp)
.webp)
